Timothy Paradis
Overview
Explore the profile of Timothy Paradis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
55
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gayle S, Paradis T, Jones K, Vasquez J, Paralkar V
Immunotherapy
. 2023 Jan;
14(18):1467-1480.
PMID: 36597724
To determine whether antigen-independent targeting of the TOP1 inhibitor exatecan to tumor with a pH-sensitive peptide (CBX-12) produces superior synergy with immunotherapy compared with unconjugated exatecan. and functional assays were...
2.
Gayle S, Aiello R, Leelatian N, Beckta J, Bechtold J, Bourassa P, et al.
NAR Cancer
. 2021 Dec;
3(4):zcab047.
PMID: 34888524
[This corrects the article DOI: 10.1093/narcan/zcab021.].
3.
Gayle S, Aiello R, Leelatian N, Beckta J, Bechtold J, Bourassa P, et al.
NAR Cancer
. 2021 Jul;
3(2):zcab021.
PMID: 34316708
Topoisomerase inhibitors are potent DNA damaging agents which are widely used in oncology, and they demonstrate robust synergistic tumor cell killing in combination with DNA repair inhibitors, including poly(ADP)-ribose polymerase...
4.
Gladue R, Paradis T, Cole S, Donovan C, Nelson R, Alpert R, et al.
Cancer Immunol Immunother
. 2011 Apr;
60(7):1009-17.
PMID: 21479995
CD40 is a member of the TNF family of receptors that has been shown to play a crucial role in enhancing dendritic cell activity and fostering anti-tumor immune responses. In...